Rubicon Research Limited (RUBICON)

Loading page…

Rubicon Research Limited (RUBICON) · mywealthgrid

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Consolidated figures · ₹ crore

₹ Cr	Mar 2026
Revenue	1,754
COGS	556
Gross profit	1,198
	798
	400
OPM %	22.8%
Depreciation	45
Interest	42
	8
Profit before tax	321
Tax	74
Tax %	23%
PAT	247
PAT margin %	14.1%
EPS (₹)	15.5
EPS adjusted (₹)	14.9
	9.7%
Annual report	Annual report for Mar 2026

₹ Cr	Mar 2025	Mar 2026
Equity capital	15	17
Reserves	526	1,272
Minority interest	0	—
	393	259
	517	779
Total equity & liabilities	1,451	2,327
	295	532
CWIP	7	40
Investments	—	27
	1,150	1,728
Total assets	1,451	2,327

₹ Cr	Mar 2025	Mar 2026
	159	205
	-65	-410
	-40	283
Net cash flow	55	78
Free cash flow	—	-24
CFO / Operating profit %	—	51.2%

Return on equity

7 years: —
5 years: —
3 years: —
Last year: 19%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2026
Margins
Gross margin %	68.3%
EBITDA margin %	22.8%
EBIT margin %	20.2%
PAT margin %	14.1%
Working capital
Receivable days	106
Inventory days	479
Payable days	248
NWC days	337
Leverage
Current ratio	2.01
Debt to EBITDA	0.65
Debt to equity	0.2
Interest coverage	8.6
Asset turnover	0.75
Return ratios
Return on assets %	10.6%
Return on capital employed %	24.3%
Return on equity %	19.1%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	59.99%	59.99%	59.86%	59.76%
	9.37%	7.99%	7.54%	7.52%
	10.54%	9.45%	10.02%	9.43%
Government	0%	0%	0%	0%
	20.1%	22.57%	22.58%	23.29%
No. of shareholders	1,05,311	31,914	33,738	43,254

Loading shareholding…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

across 8 fund houses

Held by these funds

9.73%

of the company's equity

All mutual funds

7.23%

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

25 schemes · 8 fund houses

		Shares
Portfolio of Kotak Mid Cap FundNEW	Kotak Mahindra Mutual Fund	37.78 L	687.52	0.96%	2.284%	—
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	20.24 L	368.2	4.52%	1.223%	-2.34 L
Portfolio of Kotak Large & Mid Cap FundNEW	Kotak Mahindra Mutual Fund	16.57 L	301.44	0.93%	1.002%	—
MultiCap FundNEW	SBI Mutual Fund	16.48 L	299.91	1.22%	0.997%	—
Flexi Cap FundNEW	ICICI Prudential Mutual Fund	12.05 L	219.23	0.85%	0.728%	—
Flexi Cap Fund	Bajaj Finserv Mutual Fund	8.65 L	157.48	1.82%	0.523%	-1.4 L
Portfolio of Kotak Manufacture In India Fund	Kotak Mahindra Mutual Fund	8.33 L	151.58	4.85%	0.504%	-0
ELSS- Tax Saver FundNEW	Axis Mutual Fund	8.06 L	146.57	0.45%	0.487%	—

1–8 of 25

1 / 4

Loading fund holders…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

91 announcementsExport CSV

28 Sept 2026, 6:36 pmInsider Trading / SAST

Closure of Trading Window

Closure of Trading Window PDF

29 Aug 2026, 11:14 amInsider Trading / SAST

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 PDF

27 Aug 2026, 9:18 amInsider Trading / SAST

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 PDF

26 Aug 2026, 6:04 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

AGM PDF

26 Aug 2026, 4:48 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Outcome of AGM

AGM PDF

19 Aug 2026, 11:56 amCompany Update

Announcement under Regulation 30 (LODR)-Earnings Call Transcript

Earnings Call Transcript PDF

15 Aug 2026, 12:11 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

14 Aug 2026, 10:06 pmCompany Update

Audio Recording Of Earnings Conference Call For The Quarter Ended 30Th June, 2026.

General PDF

Date	Category	Subject	Filing
28 Sept 2026, 6:36 pm	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window	PDF
29 Aug 2026, 11:14 am	Insider Trading / SAST Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011	Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

Loading announcements…

Ratio	Mar 2026
Margins
Gross margin %	68.3%
EBITDA margin %	22.8%
EBIT margin %	20.2%
PAT margin %	14.1%
Working capital
Receivable days	106
Inventory days	479
Payable days	248
NWC days	337
Leverage
Current ratio	2.01
Debt to EBITDA	0.65
Debt to equity	0.2
Interest coverage	8.6
Asset turnover	0.75
Return ratios
Return on assets %	10.6%
Return on capital employed %	24.3%
Return on equity %	19.1%

33 deals · 16 Oct 2025 – 26 Aug 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
26 Aug 2026	GENERAL ATLANTIC SINGAPORE RR PTE LTD	Bulk	BSE	Sell	1,30,09,701	₹1,660.00	₹2,159.61 Cr
26 Aug 2026	HDFC MUTUAL FUND	Bulk	BSE	Buy	48,78,009	₹1,660.00	₹809.75 Cr
26 Aug 2026	GENERAL ATLANTIC SINGAPORE RR PTE LTD	Block	BSE	Sell	48,78,009	₹1,660.00	₹809.75 Cr
26 Aug 2026	HDFC MUTUAL FUND	Block	BSE	Buy	48,78,009	₹1,660.00	₹809.75 Cr
26 Aug 2026	ICICI PRUDENTIAL MUTUAL FUND	Bulk	BSE	Buy	18,07,226	₹1,660.00	₹300.00 Cr
26 Aug 2026	ICICI PRUDENTIAL MUTUAL FUND	Block	BSE	Buy	18,07,226	₹1,660.00	₹300.00 Cr
26 Aug 2026	GENERAL ATLANTIC SINGAPORE RR PTE LTD	Block	BSE	Sell	18,07,226	₹1,660.00	₹300.00 Cr
26 Aug 2026	GENERAL ATLANTIC SINGAPORE RR PTE LTD	Block	BSE	Sell	16,56,624	₹1,660.00	₹275.00 Cr
26 Aug 2026	KOTAK MAHINDRA MUTUAL FUND	Block	BSE	Buy	16,56,624	₹1,660.00	₹275.00 Cr
26 Aug 2026	KOTAK MAHINDRA MUTUAL FUND	Bulk	BSE	Buy	16,56,624	₹1,660.00	₹275.00 Cr

1–10 of 33

1 / 4

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Rubicon Research Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Return on equity

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Investor Presentation and earnings call

Events

1

1

Announcements

Not in the F&O segment

1

1

Announcements

Annual reports

Investor Presentation and earnings call

Return on equity

Rubicon Research Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Compounded returns

Return on equity

Ratios

Ratio timeline

Shareholding

Quarterly record

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Investor Presentation and earnings call

Events

Dividends1

Board meetings1

Announcements

Ratio timeline

Not in the F&O segment

Dividends1

Board meetings1

Quarterly record

Bulk & block deals

Board and management

Announcements

Annual reports

Investor Presentation and earnings call

Profit & loss

Balance sheet

Cash flow

Compounded returns

Return on equity

1

1

1

1